Loading...
XSHG
600613
Market cap321mUSD
Jul 10, Last price  
4.73CNY
1D
-1.73%
1Q
-28.35%
Jan 2017
-67.57%
Name

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd

Chart & Performance

D1W1MN
XSHG:600613 chart
P/E
59.28
P/S
1.16
EPS
0.08
Div Yield, %
3.30%
Shrs. gr., 5y
0.49%
Rev. gr., 5y
1.43%
Revenues
1.95b
-4.71%
62,362,02065,958,55169,622,28676,975,441105,841,382148,250,092493,191,733929,184,1491,293,713,3301,592,912,4881,597,867,9211,735,715,9551,852,905,9511,927,593,2131,819,006,6912,303,032,7182,388,617,6772,340,945,5172,048,808,4501,952,370,316
Net income
38m
-46.43%
2,891,11213,790,5354,384,43405,674,00317,554,36573,430,404111,540,031180,170,062216,730,458182,059,825129,601,281106,091,39583,974,770-341,202,58669,622,54148,548,12457,000,67471,388,04838,244,070
CFO
124m
-40.10%
016,007,52125,264,7037,690,62733,035,3810074,749,395030,117,673570,41366,987,417148,525,997128,279,88899,097,235184,263,469319,232,403215,590,355207,785,516124,473,135
Dividend
Jun 05, 20250.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., through its various subsidiaries, functions as a pharmaceutical manufacturing holding and investment entity within China. The company's operations encompass the research, development, and production of a broad spectrum of medications. Its therapeutic focus includes pharmaceuticals for oncology, cardiovascular and cerebrovascular conditions, respiratory issues (such as colds and coughs), pediatric care, and antifungal treatments, alongside general health tonics. The firm's product portfolio features both prescription-only drugs and readily available over-the-counter (OTC) remedies. Established in Shanghai, China, in 1992, the company continues to operate from this location.
URL
http://www.gzsq.com/
IPO date
Aug 20, 1992
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT